XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
STATEMENTS OF CASH FLOWS - USD ($)
12 Months Ended
Feb. 28, 2022
Feb. 28, 2021
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (976,656) $ (1,203,998)
Adjustments to reconcile net loss to net cash used by operating activities:    
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D. 695,287 916,474
Forgiveness of accounts payable and accrued expenses 0 (97,773)
Changes in operating assets and liabilities    
Prepaids (385) 18,796
Accounts payable (32,512) (28,293)
Accrued liabilities (10,832) 425
NET CASH USED BY OPERATING ACTIVITIES (325,098) (394,369)
CASH FLOWS FROM FINANCING ACTIVITIES    
Contribution of capital 328,418 394,268
NET CASH PROVIDED BY FINANCING ACTIVITIES 328,418 394,268
NET INCREASE(DECREASE) IN CASH 3,320 (101)
CASH AT BEGINNING OF PERIOD 62 163
CASH AT END OF PERIOD $ 3,382 $ 62